• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cutera Announces Voluntarily Delisting from Nasdaq

    3/10/25 3:41:00 PM ET
    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CUTR alert in real time by email

    Cutera, Inc. ("Cutera" or the "Company") (NASDAQ:CUTR) today announced that it has formally notified The Nasdaq Stock Market LLC ("Nasdaq") of its intent to voluntarily delist its common stock from the Nasdaq Global Select Market. Cutera expects to file a Form 25 with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 20, 2025. The Company expects the delisting of the common stock to be effective on or about March 30, 2025. Following such delisting, the Company intends to file a Form 15 with the SEC to indefinitely suspend the Company's reporting obligations under the Securities Exchange Act of 1934, as amended. The suspension of the Company's reporting obligations, including the obligation to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, will be effective upon filing the Form 15.

    The Company has not arranged for listing or registration of the common stock on another national securities exchange or for quotation in a quotation medium and cannot guarantee that any public market for trading the common stock will exist now or in the future.

    About Cutera, Inc.

    Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. For over 25 years, Cutera has strived to improve lives through medical aesthetic technologies that are driven by science and powered through partnerships. For more information, call 1-888-4-CUTERA or visit Cutera.com.

    Safe Harbor Statement

    Certain statements in this press release, other than purely historical information, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include but are not limited to express or implied statements regarding various matters including, but not limited to, statements regarding: the Company's intention to file a Form 25 with the SEC to effect the voluntary delisting of the Common Stock on or about March 20, 2025 and to file a Form 15 with the SEC thereafter to suspend the Company's Exchange Act reporting obligations; and the potential quotation of the common stock in a quotation medium. In some cases, you can identify forward-looking statements by the use of words such as, but not limited to, "may," "could," "seek," "guidance," "predict," "potential," "likely," "believe," "will," "should," "expect," "anticipate," "estimate," "plan," "intend," "forecast," "foresee" or variations of these terms and similar expressions or the negative of these terms or similar expressions. Forward-looking statements are based on management's current expectations and beliefs and are subject to risks and uncertainties, which are difficult to predict and may cause the Company's actual results to differ materially from the express or implied forward-looking statements herein. These forward-looking statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are several risks, uncertainties, and other important factors, many of which are beyond the Company's control, that could cause its actual results to differ materially from the forward-looking statements, including risks involved with the timing and outcome of the Company's current proceedings under Chapter 11 (the "Chapter 11 Cases") and the Company's filing for relief under Chapter 11; the impact of the Chapter 11 Cases on the listing of the Company's securities on Nasdaq; as well as the other risks described in the "Risk Factors" section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other documents filed from time to time with the SEC by the Company.

    All statements made in this press release are made only as of the date of this report. Accordingly, undue reliance should not be placed on forward-looking statements. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If the Company updates one or more forward-looking statements, no inference should be drawn that it will make additional updates concerning those or other forward-looking statements.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250310151863/en/

    Cutera Media:

    Rose Temple / Evelyn Bubb

    [email protected]

    Get the next $CUTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CUTR

    DatePrice TargetRatingAnalyst
    3/22/2024Underperform → Mkt Perform
    William Blair
    7/27/2023$14.00 → $18.00Underweight → Neutral
    Piper Sandler
    5/11/2023Outperform → Mkt Perform
    William Blair
    5/10/2023$14.00Underweight
    Piper Sandler
    3/30/2023Buy → Hold
    Maxim Group
    1/31/2023Mkt Perform
    William Blair
    1/11/2023$85.00 → $33.00Overweight → Neutral
    Cantor Fitzgerald
    12/28/2022$78.00 → $68.00Overweight
    Stephens
    More analyst ratings

    $CUTR
    SEC Filings

    See more
    • SEC Form EFFECT filed by Cutera Inc.

      EFFECT - CUTERA INC (0001162461) (Filer)

      3/26/25 12:15:06 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form POS AM filed by Cutera Inc.

      POS AM - CUTERA INC (0001162461) (Filer)

      3/25/25 6:30:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 25 filed by Cutera Inc.

      25 - CUTERA INC (0001162461) (Filer)

      3/20/25 12:48:01 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CUTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Patton Stephana Eilene covered exercise/tax liability with 623 shares, decreasing direct ownership by 0.80% to 77,216 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      2/21/25 1:43:37 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Harris Taylor C. covered exercise/tax liability with 4,620 shares, decreasing direct ownership by 2% to 255,744 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      2/21/25 1:42:45 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Wierbicki Paul

      3 - CUTERA INC (0001162461) (Issuer)

      2/19/25 4:04:44 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CUTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cutera upgraded by William Blair

      William Blair upgraded Cutera from Underperform to Mkt Perform

      3/22/24 7:28:54 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Cutera from Underweight to Neutral and set a new price target of $18.00 from $14.00 previously

      7/27/23 11:27:23 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera downgraded by William Blair

      William Blair downgraded Cutera from Outperform to Mkt Perform

      5/11/23 7:25:52 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care